+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index



A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index



Plos One 8(12): E83081



The aim of this study was to evaluate clinicopathologic factors that could possibly affect the outcome of patients with triple negative breast cancer and subsequently build a prognostic model to predict patients' outcome. We retrospectively analyzed clinicopathologic characteristics and outcome of 504 patients diagnosed with triple-negative invasive ductal breast cancer. 185 patients enrolled between 2000 and 2002 were designated to the training set. The variables that had statistically significant correlation with prognosis were combined to build a model. The prognostic value of the model was further validated in the separate validation set containing 319 patients enrolled between 2003 and 2006. The median follow-up duration was 66 months. 174 patients experienced recurrence, and 111 patients died. Positivity for ≥4 lymph nodes, Cathepsin-D positivity, and Ki-67 index ≥20% were independent factors for DFS, while the lymph nodes status and Ki-67 index were the prognostic factors for OS. The prognostic model was established based on the sum of all three factors, where positivity for ≥4 lymph nodes, Cathepsin-D and Ki-67 index ≥20% would individually contribute 1 point to the risk score. The patients in the validation set were assigned to a low-risk group (0 and 1 point) and a high-risk group (2 and 3 points). The external validation analysis also demonstrated that our prognostic model provided the independent high predictive accuracy of recurrence. This model has a considerable clinical value in predicting recurrence, and will help clinicians to design an appropriate level of adjuvant treatment and schedule adequate appointments of surveillance visits.

(PDF emailed within 1 workday: $29.90)

Accession: 051219547

Download citation: RISBibTeXText

PMID: 24340082


Related references

A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. Plos One 9(6): E100664, 2015

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Research and Treatment 134(1): 277-282, 2012

A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial. Annals of Oncology 24(9): 2284-2291, 2014

A Prognostic Model for Patients with Triple-Negative Breast Cancer: Importance of the Modified Nottingham Prognostic Index and Age. Journal of Breast Cancer 20(1): 65-73, 2017

Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clinical Cancer Research 6(2): 578-584, 2000

Cathepsin d and other markers as prognostic indicators for node negative breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 32: 164, 1991

Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Research and Treatment 60(2): 173-179, 2000

Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Research 52(19): 5198-5203, 1992

A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Research and Treatment 132(2): 499-509, 2012

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. Plos One 10(12): E0144359-E0144359, 2016

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 118(13): 3236-3243, 2012

New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. Oncotarget 7(17): 24824-24831, 2017

Integrative 3' Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. Oncologist 2018, 2018

Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. International Journal of Oncology 18(4): 793-800, 2001

Ki67 Is it a prognostic index in node negative breast cancer patients?. European Journal of Cancer 37(Supplement 6): S121, 2001